## ACLX: Arcellx, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -13.3% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($60.44)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Optimistic Buy Rating for Arcellx Inc: Promising Anito-cel Therapy and Strategic Advancements**
- Source: TipRanks | 20251208T022055 | Bullish | Relevance: 99%
-  Morgan Stanley analyst Judah Frommer maintained a Buy rating on Arcellx Inc (NASDAQ: ACLX) with a $111.00 price target, citing promising developments in their anito-cel therapy for multiple myeloma, highlighted by updated efficacy and safety data. The anticipated Biologics License Application (BLA) acceptance and a projected US launch in 2026, alongside strategic partnerships, support this optimistic outlook. Bank of America Securities also reiterated a Buy rating with a $112.00 price target.

**2. ASH 2025: Arcellx and Gilead’s Anito-cel challenges CAR-T market in R/R MM**
- Source: Clinical Trials Arena | 20251209T120929 | Bullish | Relevance: 99%
- At ASH 2025, updated results from the Phase II iMMagine-1 clinical trial of Arcellx and Gilead's anito-cel for relapsed/refractory multiple myeloma (R/R MM) were presented, showing strong efficacy with a 96% overall response rate and a manageable safety profile. Anito-cel is positioned as a strong competitor to existing CAR-T therapies like J&J/Legend's Carvykti, with sales projected to reach $658 million by 2032. The ongoing Phase III iMMagine-3 trial aims to expand its label into earlier treatment lines, potentially establishing it as a best-in-class option.

**3. Arcellx announces new data for its iMMagine-1 study in patients with RRMM**
- Source: TipRanks | 20251207T172055 | Bullish | Relevance: 99%
-  Arcellx (ACLX) announced positive new data from its pivotal Phase 2 iMMagine-1 study for anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma (RRMM). The data, presented at the 67th American Society of Hematology Annual Meeting, showed a 96% overall response rate and high rates of complete response and MRD negativity. The therapy demonstrated strong progression-free and overall survival rates over 24 months, with median PFS and OS not yet reached.

**4. Arcellx Inc. (ACLX) Stock Price | Live Quotes & Charts | NASDAQ**
- Source: StocksToTrade | 20251208T191005 | Bullish | Relevance: 99%
-  This article provides live stock quotes and charts for Arcellx Inc. (ACLX) on NASDAQ. It shows the current stock price, daily change, and includes a candlestick line chart. The article also touches on analyst ratings and earnings, noting a lack of information for Arcellx Inc.

**5. Arcellx stock soars after positive multiple myeloma therapy data**
- Source: Investing.com | 20251208T131005 | Bullish | Relevance: 98%
-  Arcellx Inc (NASDAQ:ACLX) stock surged over 13% in premarket trading after reporting compelling data from its pivotal Phase 2 study of anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma. The therapy showed high overall response rates, profound complete response rates, and significant progression-free and overall survival rates, with no new safety concerns. Arcellx, in partnership with Gilead's Kite, plans a commercial launch in 2026.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Canaccord Genui | $130 | $130 | 0% |
| 2025-12-08 | Needham | $105 | $105 | 0% |
| 2025-11-18 | Wolfe Research | $0 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Canaccord Genui | main | Buy |
| 2025-12-08 | Needham | reit | Buy |
| 2025-11-18 | Wolfe Research | init | Peer Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 9 ($2.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 1 / 5 |

**Top Holders:**
- Gilead Sciences Inc: 11.6% (0.0%)
- T. Rowe Price Invest: 11.0% (+226.8%)
- FMR, LLC: 10.0% (-3.5%)
- Paradigm Biocapital : 8.0% (0.0%)
- Vanguard Group Inc: 6.8% (-1.0%)

### Key Risks

1. Elevated short interest (13.9%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.49). Revenue growth strong at 288% YoY. Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (1 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.1B |
| Beta | 0.34 |
| 52W Range | $47.86 - $94.07 |
| Short Interest | 13.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 improving modestly (+0.6% over 5 days). Below STRENGTH zone by 17.3pp (needs >4.0% for momentum thesis). AM_20 at -11.2% indicates price below own 20MA trend. Underperforming sector by 8.8pp, stock-specific weakness. Below SMA200 (0.99x), long-term trend not supportive. MACD histogram bearish (-0.91), momentum weakening. Elevated volume (1.9x 20MA), institutional activity likely.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -13.30% (CS: 0) | Weak |
| RSI_14 | 37.9 | Neutral |
| MACD Histogram | -0.91 | Bearish |
| vs SMA20 | 0.888x | Below |
| vs SMA50 | 0.846x | Below |
| vs SMA200 | 0.992x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $70.84
- **Stop Loss:** $60.44 (14.7% risk)
- **Target:** $81.24 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 28
- **Position Value:** $1,983.52
- **Portfolio %:** 1.98%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-26 (Est: $-1.06)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.03 | $-0.99 | +4.1% |
| 2025Q2 | $-1.03 | $-0.94 | +8.9% |
| 2025Q1 | $-0.74 | $-1.13 | -53.0% |
| 2024Q4 | $-0.47 | $-0.87 | -83.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*